Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Hepatocellular Carcinoma – Epidemiology – Epidemiology Dashboard

Login to access report north_east
Contact sales account_box

Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed incident of hepatocellular carcinoma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

Hepatocellular carcinoma forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s hepatocellular carcinoma forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of hepatocellular carcinoma and the number of new diagnoses of hepatocellular carcinoma?
  • Of all people diagnosed with hepatocellular carcinoma, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of hepatocellular carcinoma over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following hepatocellular carcinoma subpopulations:

  • Diagnosed incident cases
  • Diagnosed early incident cases
  • Diagnosed intermediate incident cases
  • Diagnosed advanced incident cases
  • Diagnosed prevalent population
  • Recurrent incident cases
  • Drug treatable and drug treated populations

Note: Coverage may vary by country

Table of contents

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Small-Cell Lung Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for small-cell lung cancer (SCLC) has seen significant advances in the past few years. Previously, chemotherapy and radiotherapy were the predominant treatments, but…
north_east
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
north_east
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
north_east
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
north_east
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east